Trial site
Pinnacle Clinical Research - San Antonio
San Antonio, Texas 78222, United StatesNot linked to an institution yet
- 8running trials
- 4closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 36 trials
- Status
- Active, not recruiting4 trials
- Completed4 trials
- Recruiting4 trials
- Lead sponsor
- Boehringer Ingelheim2 trials
- Madrigal Pharmaceuticals, Inc.2 trials
- GlaxoSmithKline1 trial
- HighTide Therapeutics (Hong Kong) Limited1 trial
- Hoffmann-La Roche1 trial
- and 5 more
Running trials
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458· Phase 2· Rivus Pharmaceuticals, Inc.· Source
Contact: Mary Lou Hernandez
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error